FY2026 EPS Estimates for AstraZeneca Increased by Analyst

AstraZeneca PLC (NASDAQ:AZN) – Equities research analysts at Leerink Partnrs boosted their FY2026 EPS estimates for shares of AstraZeneca in a research note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst A. Berens now forecasts that the company will earn $6.08 per share for the year, up from their prior estimate of $6.05. The consensus estimate for AstraZeneca’s current full-year earnings is $4.12 per share.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 EPS.

Several other research firms have also commented on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.4 %

NASDAQ AZN opened at $68.20 on Wednesday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca has a one year low of $60.47 and a one year high of $87.68. The company has a 50-day simple moving average of $66.20 and a 200-day simple moving average of $74.32. The firm has a market capitalization of $211.49 billion, a PE ratio of 32.63, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46.

Institutional Investors Weigh In On AstraZeneca

Institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after buying an additional 1,605,758 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock worth $1,492,649,000 after purchasing an additional 1,522,715 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in AstraZeneca by 65.1% during the second quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after buying an additional 950,000 shares in the last quarter. Erste Asset Management GmbH acquired a new position in AstraZeneca in the third quarter worth approximately $72,437,000. Finally, Fisher Asset Management LLC increased its holdings in shares of AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after buying an additional 524,175 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.